Informations

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Pratima Chowdary from the Katherine Dormandy Haemophilia and Thrombosis Centre at Royal Free Hospital, University College London (UCL), delivered an in-depth presentation titled “The future of hemophilia care: Entering an era of personalized medicine.” Professor Chowdary reviewed the evolution of hemophilia care over nearly a…

At the 2026 European Hematology Association (EHA) Annual Meeting, world-renowned lymphoma expert Professor Stephen Ansell from the Mayo Clinic (Rochester, Minnesota, USA) was invited to deliver a keynote speech titled “Deciphering HL biology.” Professor Ansell systematically reviewed the molecular origins of Reed-Sternberg (RS) cells in classical Hodgkin lymphoma (cHL), the abnormal activation of key signaling…

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Todd Knepper from Moffitt Cancer Center shared a thematic report on “Post-Transplant Molecular Surveillance Reveals Divergent Clinical Trajectories of Donor-Derived Clonal Hematopoiesis (DD-CHIP).” Through high-throughput sequencing (NGS) technology, this study explored the incidence, molecular landscape, and differentiated impact of DD-CHIP on clinical outcomes in recipients…

The treatment of multiple myeloma (MM) has entered the era of immunotherapy. In particular, the emergence of Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved the prognosis of patients with relapsed/refractory multiple myeloma (R/R MM). However, challenges such as resistance caused by antigen loss, prolonged manufacturing cycles (vein-to-vein time), and potential severe toxicities remain…

In June 2026 local time, the European Hematology Association (EHA) Annual Congress was grandly held. In the Multiple Myeloma (MM) session, top global hematology experts engaged in in-depth dialogues regarding the treatment pathways for newly diagnosed multiple myeloma (NDMM), liquid biopsy for prognostic assessment, and intensified treatment regimens for ultra-high risk patients. This session was…

In the era of rapidly evolving immunotherapy, determining the optimal bridging strategy to hematopoietic stem cell transplantation (HSCT) for patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a major clinical challenge. At EHA 2026, Prof. Meng Lü and colleagues from Peking University People’s Hospital presented an important oral study based on a large…

As targeted therapies continue to transform the treatment landscape of chronic lymphocytic leukemia (CLL), therapeutic goals are evolving beyond long-term disease control toward deeper remissions, fixed-duration treatment strategies, and even the possibility of functional cure. At EHA 2026, several landmark studies provided important evidence supporting this paradigm shift.